STAT+: Bluebird, troubled gene therapy maker, to lay off employees and reduce costs
Bluebird Bio is reducing expenses and laying off nearly a third of its employees to preserve cash ahead of two pivotal, gene therapy approval decisions expected later this year, the company said Tuesday.
The restructuring, which aims to save $160 million over the next two years, comes one month after Bluebird warned investors there was “substantial doubt” about its ability to remain solvent beyond this year.
